期刊
LEUKEMIA
卷 -, 期 -, 页码 -出版社
SPRINGERNATURE
DOI: 10.1038/s41375-022-01786-9
关键词
-
资金
- Nohla Therapeutics (now Deverra Therapeutics)
Contemporary data on infections after intensive chemotherapy for acute myeloid leukemia (AML) are scarce. Patients receiving CLAG-M for newly diagnosed or relapsed/refractory AML have higher rates of moderate to severe infections, especially in the case of relapsed/refractory disease. Improved strategies for infection prevention are needed.
Contemporary data on infections after intensive chemotherapy for acute myeloid leukemia (AML) are scarce. Cladribine, high-dose cytarabine, G-CSF, and dose-escalated mitoxantrone ( CLAG-M ) may result in higher remission rates than standard-dose cytarabine plus anthracycline ( 7 + 3 ) but may result in more infections. We compared moderate to severe infections occurring up to 90 days after the first induction cycle for AML or other high-grade myeloid neoplasms in patients receiving CLAG-M for newly diagnosed (n = 196) or relapsed/refractory disease (n = 131) or 7 + 3 for newly diagnosed disease (n = 115). For newly diagnosed disease, microbiologically documented infections were more frequent after CLAG-M compared to 7 + 3 (adjusted rate ratio, 1.65 [95% CI, 1.06-2.58]; P = 0.03), with a cumulative incidence of 27.8% and 16.5% by day 90, respectively. Patients receiving CLAG-M for relapsed/refractory disease had the highest cumulative incidence of 50.7%. Bacterial bloodstream infections were the most frequent followed by respiratory tract infections. Among 29 patients (7%) who died, infection was a primary or contributing cause of death in 59%. These data indicate that infections continue to cause substantial morbidity in patients treated for AML, especially those treated for relapsed/refractory disease, and are more common with newer, more myelosuppressive regimens such as CLAG-M. Improved strategies for infection prevention are needed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据